Project Overview
Diclofenac sodium slow release (SR) tablets 100mg are a formulation of the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium designed to provide a prolonged therapeutic effect. The slow release mechanism allows for a gradual release of the active ingredient over an extended period, which can enhance the efficacy of pain relief while reducing the frequency of dosing. This formulation is particularly beneficial for chronic conditions such as arthritis, where consistent pain management is crucial. The SR tablets aim to improve patient adherence and comfort by minimizing the peaks and troughs of drug levels in the bloodstream, thus enhancing the overall treatment experience. With a strong emphasis on patient-centered healthcare and advancements in drug delivery technologies, the market for slow-release formulations is on the rise, creating opportunities for pharmaceutical companies to innovate and expand their product offerings. The demand for such products is propelled by an increasing prevalence of chronic pain conditions and an aging population that often suffers from musculoskeletal disorders. Regulatory approvals and patent protections further add to the market dynamics, providing companies with avenues for strategic alliances and partnerships within the pharmaceutical sector.
Market Potential
- Growing prevalence of chronic pain conditions increasing demand for effective pain management solutions.
- Rising geriatric population leading to higher incidences of conditions like arthritis.
- Increased awareness and preference for slow-release formulations among patients and healthcare providers.
- Potential for expansion in emerging markets due to improving healthcare infrastructure.
SWOT Analysis
Strengths
- Effective pain management with prolonged drug release.
- High patient compliance due to reduced dosing frequency.
- Established safety and efficacy profile of diclofenac sodium.
Weaknesses
- Potential for side effects associated with NSAIDs.
- Market competition from other pain management drugs.
- Dependence on regulatory approvals which can delay market entry.
Opportunities
- Development of combination therapies to enhance efficacy.
- Expansion into new markets with growing healthcare needs.
- Technological advancements in drug delivery systems.
Threats
- Stringent regulatory environment with continuous changes.
- Generic competition affecting market share.
- Shifts in treatment guidelines or preferences towards alternative therapies.
Raw Materials Required
- Diclofenac sodium
- Polymer matrix (for slow release)
- Excipients (binding agents, fillers)
- Coating materials (for controlled release)
Investment Profiles & Financial Analysis
This project has 4 investment scales. Select a profile to view its figures.
Micro
Feasible for niche markets with minimal investment.
Small
Suitable for small-scale operations with good ROI.
Medium
Promising returns with sufficient market demand.
Large
High initial investment but substantial market potential.
Frequently Asked Questions
What is this project about?
Diclofenac sodium slow release (SR) tablets 100mg are a formulation of the non-steroidal anti-inflammatory drug (NSAID) diclofenac sodium designed to provide a prolonged therapeutic effect. The slow release mechanism allows for a gradual release of the active ingredient over an extended period, which can enhance the efficacy of pain relief while reducing the frequency of dosing. This formulation is particularly beneficial for chronic conditions such as arthritis, where consistent pain management is crucial. The SR tablets aim to improve patient adherence and comfort by minimizing the peaks and troughs of drug levels in the bloodstream, thus enhancing the overall treatment experience. With a strong emphasis on patient-centered healthcare and advancements in drug delivery technologies, the market for slow-release formulations is on the rise, creating opportunities for pharmaceutical companies to innovate and expand their product offerings. The demand for such products is propelled by an increasing prevalence of chronic pain conditions and an aging population that often suffers from musculoskeletal disorders. Regulatory approvals and patent protections further add to the market dynamics, providing companies with avenues for strategic alliances and partnerships within the pharmaceutical sector.
What is the market potential?
• Growing prevalence of chronic pain conditions increasing demand for effective pain management solutions.
• Rising geriatric population leading to higher incidences of conditions like arthritis.
• Increased awareness and preference for slow-release formulations among patients and healthcare providers.
• Potential for expansion in emerging markets due to improving healthcare infrastructure.
How much investment is required?
Total capital investment ranges from ₹440,000 to ₹28,600,000 depending on the scale of operation. This covers plant and machinery, civil work, pre-operative expenses, and working capital. Larger scales require proportionally higher investment but typically offer better returns.
When does this project break even?
At the larger investment scale, the expected break-even is approximately approx. 5 years at approximately 75.00% capacity utilisation. Smaller setups may reach break-even sooner due to lower fixed costs relative to the capacity.
What raw materials are required?
• Diclofenac sodium
• Polymer matrix (for slow release)
• Excipients (binding agents, fillers)
• Coating materials (for controlled release)
What are the key strengths of this project?
• Effective pain management with prolonged drug release.
• High patient compliance due to reduced dosing frequency.
• Established safety and efficacy profile of diclofenac sodium.
Related topics